Form 8-K - Current report:
SEC Accession No. 0001558370-21-000807
Filing Date
2021-02-08
Accepted
2021-02-08 16:14:19
Documents
16
Period of Report
2021-02-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K neos-20210205x8k.htm   iXBRL 8-K 57893
2 EX-10.1 neos-20210205xex10d1.htm EX-10.1 114175
3 EX-10.2 neos-20210205xex10d2.htm EX-10.2 112410
4 EX-10.3 neos-20210205xex10d3.htm EX-10.3 102432
5 EX-10.4 neos-20210205xex10d4.htm EX-10.4 120798
  Complete submission text file 0001558370-21-000807.txt   723051

Data Files

Seq Description Document Type Size
6 EX-101.SCH neos-20210205.xsd EX-101.SCH 3231
7 EX-101.LAB neos-20210205_lab.xml EX-101.LAB 16155
8 EX-101.PRE neos-20210205_pre.xml EX-101.PRE 10951
9 EXTRACTED XBRL INSTANCE DOCUMENT neos-20210205x8k_htm.xml XML 4809
Mailing Address 2940 N. HIGHWAY 360 SUITE 400 GRAND PRAIRIE TX 75050
Business Address 2940 N. HIGHWAY 360 SUITE 400 GRAND PRAIRIE TX 75050 972.408.1360
Neos Therapeutics, Inc. (Filer) CIK: 0001467652 (see all company filings)

EIN.: 270395455 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37508 | Film No.: 21601576
SIC: 2834 Pharmaceutical Preparations